Shots:
- Third Arc Bio has entered into a licensing agreement with Adagene to utilize its SAFEbody technology platform for generating masked CD3 T cell engagers against unique tumor-associated antigens
- As per the deal, Third Arc Bio will gain global rights to research, develop & commercialize 2 candidate molecules, while Adagene will receive a no-cost option to develop & commercialize the molecules in Greater China, Singapore, & South Korea
- Under the deal, Adagene will receive $5M upfront & is eligible to receive ~$840M in development & commercial milestones, with royalties on end-user sales
Ref: Adagene | Image: Adagene & Third Arc Bio | Press Release
Related News:- Chiesi Group Collaborates with Aliada Therapeutics to Develop Enzyme Replacement Therapies for Lysosomal Storage Disorders
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
